RNA isolation kit market to reach $2.72 billion by 2030

The global RNA isolation kit market is projected to grow from $1.76 billion in 2025 to $2.72 billion by 2030, driven by infectious disease testing, molecular biology research and automation. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - RNA isolation kits are a core tool for research and molecular diagnostics because they extract and purify RNA from biological samples. - Market growth signals more demand for workflows tied to infectious disease testing, genomics, transcriptomics and precision medicine. - The market’s expansion also reflects broader adoption of automated and high-throughput lab systems.

What happened: - The Business Research Company released its Ribonucleic Acid (RNA) Isolation Kit Global Market Report 2026 covering market size, trends and forecasts for 2026-2035. - The global RNA isolation kit market was valued at $1.76 billion in 2025. - The market is projected to reach $1.93 billion in 2026, implying 9.4% annual growth. - The market is forecast to rise to $2.72 billion by 2030, at a 9.0% CAGR. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific will be the fastest-growing region during the forecast period. - Download a free sample of the report - View the full report

The details: - RNA isolation kits separate RNA from proteins, DNA and lipids while preserving RNA integrity and quality. - The kits support downstream research, molecular diagnostics and analytical applications. - Historical growth has been supported by more molecular biology funding, expanded genomics and transcriptomics studies, rising infectious disease cases, wider use of lab automation and advances in column-based and spin-based extraction technologies. - Future growth is expected to be supported by AI-assisted workflow optimization, precision medicine demand, point-of-care diagnostics, automated high-throughput extraction systems and more research into cell-free and exosomal RNA. - Rising infectious disease prevalence is a key driver because high-quality RNA is needed for accurate molecular diagnosis and pathogen detection. - CDC data cited in the report show U.S. tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, an increase of 1,295 cases. - Additional growth drivers include automated magnetic bead-based extraction methods, contamination-resistant reagents, ultra-low input and single-cell RNA workflows, viral RNA kits for infectious disease diagnostics and portable point-of-care extraction solutions. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Between the lines: - Demand is moving beyond basic lab research toward faster, more distributed testing models. - The strongest growth themes point to automation, decentralization and higher-sensitivity workflows, which suggests buyers want speed and scale without sacrificing sample quality. - The regional split also shows a mature installed base in North America and a faster buildout phase in Asia-Pacific.

What's next: - The market is expected to keep expanding as diagnostics, single-cell research and automated extraction systems gain broader use. - Companies focused on magnetic bead workflows, contamination control and portable extraction tools may benefit most from demand tied to decentralized testing. - The regional growth gap between North America and Asia-Pacific will likely shape competition, investment and product launches through 2030.